Ocera to Present at
Ocera to Present at the Cowen and Company 36th Annual Health Care Conference
29 févr. 2016 16h05 HE | Ocera Therapeutics, Inc.
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and...
Oncothyreon Announce
Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast Cancer
29 févr. 2016 08h00 HE | Cascadian Therapeutics, Inc.
--Study to Evaluate ONT-380 in Combination with Herceptin and Xeloda-- --Study Will Enroll HER2-Positive Breast Cancer Patients With and Without Brain Metastases-- SEATTLE, Feb. 29, 2016 (GLOBE...
Dendritic Cell Vacci
Dendritic Cell Vaccine Inhibits Tumor Progression in Preclinical Liver Cancer Model
25 févr. 2016 12h16 HE | Saronic Biotechnology, Inc.
NEW YORK, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc. today announces publication of preclinical data of autologous dendritic cell (DC) vaccine treatment in a murine model for...
Phase 1b Clinical Tr
Phase 1b Clinical Trial of BPZE1 Pertussis Vaccine Completes Enrollment of Randomized Study Groups
19 févr. 2016 09h55 HE | ILiAD Biotechnologies, LLC
NEW YORK, Feb. 19, 2016 (GLOBE NEWSWIRE) -- ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotechnology company, announced today that enrollment has been completed for three randomized groups...
Achillion-Logo-150 (4).jpg
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
11 févr. 2016 06h05 HE | Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...
Human Validation Dat
Human Validation Data Supporting Saronic Biotechnology’s Lead Therapeutic SBI1997 Published in the Journal of Immunotherapy
09 févr. 2016 11h10 HE | Saronic Biotechnology, Inc.
NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc., a U.S. biotechnology company dedicated to developing novel immunotherapeutics for liver cancer, today announces the...
Radiant Sage Expands Service Offering in Europe Through Partnership With Clearpoint Image Review Center
02 févr. 2016 10h19 HE | Radiant Sage
BELMONT, MA and OSLO, NORWAY--(Marketwired - Feb 2, 2016) - Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions and services, today announced that it has...
Agile_Logo-color on white.jpg
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
22 janv. 2016 09h16 HE | Agile Therapeutics, Inc.
PRINCETON, N.J., Jan. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company focused on the development and commercialization of...
Summit Master_rgb_png.png
Summit Therapeutics Receives Regulatory Approval to Initiate PhaseOut DMD, a Phase 2 Clinical Trial of SMT C1100 in Patients With DMD
21 janv. 2016 07h00 HE | Summit Therapeutics plc
OXFORD, UK, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (LSE:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’)...
Radiant Sage Appoints Robert Ford, MD, as Adjunct Chief Medical Advisor
12 janv. 2016 10h58 HE | Radiant Sage
BELMONT, MA--(Marketwired - Jan 12, 2016) - Radiant Sage LLC, a provider of on-demand clinical trial imaging infrastructure solutions and services, today announced that Robert Ford, MD, has been...